—Yes, say the authors of a new study, which found that a mere 5% of routine follow-up visits among patients with diffuse large B-cell lymphoma (DLBCL) in remission resulted in detection of relapse.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

The mutation burden in DLBCL varies significantly based on patient sex and age, according to recent findings published in ...

Around 40% of people with DLBCL relapse after initial therapy, so boosting responses in the front-line setting has the potential to provide big benefits to patients and reduce the need for later ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

Each year in Europe, an estimated 38,000 people are diagnosed with DLBCL. 4,5 Approximately four out of ten patients will relapse after first line treatment and the majority of patients who ...

More than 18,000 people are diagnosed with DLBCL each year. About 30–40% of patients will experience relapse, most of them within the first two years. MRD testing can help doctors assess ...